文献速递眼底病与葡萄膜炎

成人型卵黄样黄斑营养不良与年龄相关性黄斑变性存在遗传重叠

Adult Onset Foveomacular Vitelliform Dystrophy Shows Genetic Overlap With Age-Related Macular Degeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

研究纳入50例成人型卵黄样黄斑营养不良(AFVD)、917例年龄相关性黄斑变性(AMD)患者及432名健康对照,检测52个AMD相关单核苷酸多态性并计算加权遗传风险评分。结果显示AFVD与补体通路AMD风险等位基因相关,而其他通路遗传风险评分呈负相关。

要点

  • AFVD与补体通路AMD风险等位基因相关,但与其它通路遗传风险评分呈负相关。
  • CFH(rs570618)与AFVD风险升高相关,C2/CFB/SKIV2L两个变异与风险降低相关。
  • MIR6130/RORB(rs10781182)与AFVD和AMD均呈负相关。

核心结论

  • 非单基因型AFVD与补体级联中的AMD风险等位基因相关,但与其他通路无关。
  • 作者认为需进一步研究探索补体抑制用于AFVD。

研究设计与样本

  • 研究收集50例AFVD患者(男/女=25/25,平均年龄±标准差73±10岁)、917例AMD患者(男/女=377/540,平均年龄±标准差77±9岁)和432名健康对照(男/女=202/230,平均年龄±标准差71±8岁)的临床、影像和遗传数据。
  • 基因分型聚焦52个与AMD相关的单核苷酸多态性(SNP),并计算19个补体系统相关变异、7个脂质代谢相关变异、其余26个变异(其他通路GRS)及全部52个变异(全局评分)的加权遗传风险评分(GRS)。

主要发现

  • 与健康对照相比,CFH(rs570618)与AFVD相关(OR=2.73,95%CI=1.32-5.73,P=0.01)。
  • 与健康对照相比,C2/CFB/SKIV2L(rs116503776和rs114254831)与AFVD相关(OR=0.31,95%CI=0.14-0.71,P=0.0036;OR=0.41,95%CI=0.22-0.74,P=0.0025)。
  • 与健康对照相比,MIR6130/RORB(rs10781182)与AFVD负相关(OR=0.13,95%CI=0.06-0.25,P<0.0001);与AMD相比亦负相关(OR=0.19,95%CI=0.10-0.34,P<0.0001)。
  • 与对照相比,补体GRS与AFVD正相关(OR=1.42,95%CI=1.04-1.95,P=0.03),其他通路GRS与AFVD负相关(OR=0.46,95%CI=0.21-0.98,P=0.04)。
  • 与对照相比,AMD与补体评分、全局评分及ARMS2/HTRA1正相关。

关键数值与推荐

  • AFVD与健康对照比较:CFH(rs570618)OR=2.73(95%CI=1.32-5.73,P=0.01)。
  • AFVD与健康对照比较:C2/CFB/SKIV2L(rs116503776)OR=0.31(95%CI=0.14-0.71,P=0.0036)。
  • AFVD与健康对照比较:C2/CFB/SKIV2L(rs114254831)OR=0.41(95%CI=0.22-0.74,P=0.0025)。
  • AFVD与健康对照比较:MIR6130/RORB(rs10781182)OR=0.13(95%CI=0.06-0.25,P<0.0001);AFVD与AMD比较:OR=0.19(95%CI=0.10-0.34,P<0.0001)。
  • AFVD与对照比较:补体GRS OR=1.42(95%CI=1.04-1.95,P=0.03),其他通路GRS OR=0.46(95%CI=0.21-0.98,P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究探索补体抑制用于AFVD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adult-onset foveomacular vitelliform dystrophy (AFVD) shares phenotypic similarities with age-related macular degeneration (AMD). The genetic factors associated with AFVD are unknown in >80% of cases. This study evaluated the association of known AMD genetic risk variants with AFVD and compared systemic complement activation in these conditions. METHODS: Clinical, imaging, and genetic data were collected from 50 patients with AFVD (men/women = 25/25, mean age ± SD 73 ± 10 years), 917 patients with AMD (men/women = 377/540, mean age ± SD 77 ± 9 years), and 432 unaffected healthy controls (men/women = 202/230, mean age ± SD 71 ± 8 years). Genotyping focused on 52 single nucleotide polymorphisms (SNPs) linked to AMD. Weighted genetic risk scores (GRS) for 19 complement system associated variants, 7 lipid metabolism associated variants, the remaining 26 variants (other pathways GRS), and for all 52 variants (global score) were derived and correlated with phenotype. RESULTS: Of the 52 SNPs evaluated, CFH (rs570618) and C2/CFB/SKIV2L (rs116503776 and rs114254831) were associated with AFVD compared with healthy controls (odds ratio [OR] = 2.73, 95% confidence interval [CI] = 1.32-5.73, P = 0.01; OR = 0.31, 95% CI = 0.14-0.71, P = 0.0036; and OR = 0.41, 95% CI = 0.22-0.74, P = 0.0025, respectively). MIR6130/RORB (rs10781182) was negatively associated with AFVD compared with the healthy controls (OR = 0.13, CI = 0.06-0.25, P < 0.0001) and AMD (OR = 0.19, CI = 0.10-0.34, P < 0.0001). Regression analysis showed complement GRS was positively associated with AFVD compared with controls (OR = 1.42, 95% CI = 1.04-1.95, P = 0.03), whereas the other pathways' GRS was negatively associated (OR = 0.46, 95% CI = 0.21-0.98, P = 0.04). AMD was positively associated with the complement score, global score, and ARMS2/HTRA1 compared with controls. CONCLUSIONS: Non-monogenic AFVD is associated with AMD risk alleles in the complement cascade, but not in other pathways. Further research is needed to explore complement inhibition for AFVD.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Jaskoll S, Kramer A, Elbaz-Hayoun S, et al. Adult Onset Foveomacular Vitelliform Dystrophy Shows Genetic Overlap With Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2024. PMID: 39585675. doi:10.1167/iovs.65.13.53

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。